# BLIND POINT-IN-TIME FORECASTING TASK
You are a professional regulatory forecaster. This file contains 20 independent forecasting snapshots about
DIFFERENT regulatory matters. Treat each snapshot on its own; do not carry information between snapshots.

Rules:
1. For each snapshot, "today" is its CUTOFF DATE. Use only the evidence shown plus general knowledge of how the
   regulatory process usually behaves (base rates, typical durations). Do not use any world-state fact learned after
   the cutoff: later election results, leadership changes, court rulings, agency decisions, dates or outcomes are
   unknown, even if you remember them. A future event stated in cutoff-valid evidence may be considered only as an
   uncertain plan or possibility, never as a later-known result. Every factual driver in "notes" or "scenarios" must
   be supported by the shown evidence or be a general process base rate.
2. Do NOT use any specific memory of what happened to this particular matter after the cutoff. If you recognise the
   matter and believe you know its later outcome, set "recognised_outcome": true and forecast from cutoff-valid
   evidence only. Never state or hint at the remembered result.
3. The evidence shown may be only a subset of what was public; do not infer anything from the absence of a
   document type. Some snapshots show no documents at all — then forecast from title, regulator, process and date.
4. "Decisive action" is defined per snapshot. Probabilities in "p" are CUMULATIVE: probability the decisive action
   is published within 7/30/60/90/180 days AFTER the cutoff (non-decreasing; "180d" is the headline action
   probability). Delays, stalls, withdrawals and no-action outcomes are common in regulation: be calibrated, use
   the full 0–1 range when evidence warrants, and do not default to 0.5.
5. "next": the NEXT official step within 180 days (mutually exclusive, sums to 1): final_action,
   revised_or_further_consultation (revised draft, supplemental proposal, extended/reopened comment period,
   further consultation or hearing), formal_withdrawal, no_further_official_step.
6. "content": CONDITIONAL on the decisive action happening, its form relative to the most recent proposal visible
   (sums to 1): as_proposed (substantially as proposed), softened (narrower scope, lower stringency, higher
   thresholds, longer transition, carve-outs), tightened, mixed (some softened, some tightened),
   different_mechanism.
7. "scenarios": up to 3 concrete policy-content scenarios CONDITIONAL on action (probabilities sum ≤ 1), each with
   a short mechanism and, where the evidence has numbers (thresholds, rates, dates, amounts), predicted
   parameter ranges. Cite evidence labels (E1, E2 …) that support/contradict it.
8. If the evidence is too thin to forecast meaningfully, set "insufficient_evidence": true but still give your best
   base-rate probabilities.

OUTPUT: read the output file named in your instructions (it contains a placeholder) and replace its ENTIRE content
with ONE JSON object of exactly this shape (no comments, no trailing text):
{"forecasts": [
  {"id": "<snapshot id>",
   "p": {"7d": 0.00, "30d": 0.00, "60d": 0.00, "90d": 0.00, "180d": 0.00},
   "next": {"final_action": 0.00, "revised_or_further_consultation": 0.00, "formal_withdrawal": 0.00, "no_further_official_step": 0.00},
   "content": {"as_proposed": 0.00, "softened": 0.00, "tightened": 0.00, "mixed": 0.00, "different_mechanism": 0.00},
   "scenarios": [{"s": "short label", "p": 0.00, "mech": "mechanism, <=25 words", "params": {"parameter": "predicted range"}, "ev": ["E1"], "contra": []}],
   "notes": "<=40 words: main drivers of your forecast",
   "missing": ["<=3 items of missing information that would most change the forecast"],
   "recognised_outcome": false,
   "insufficient_evidence": false}
]}
One entry per snapshot, in any order, using the exact snapshot ids below.

---
## SNAPSHOT Sb494b14670
CUTOFF DATE (today): 2022-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Mitigation Strategies To Protect Food Against Intentional Adulteration
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S30eb2d8569
CUTOFF DATE (today): 2026-08-25
Regulator: SEBI (IN)
Matter: SEBI consultation: standardising the process for opening mutual fund folios and executing the first investment
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sa7b4126310
CUTOFF DATE (today): 2023-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations ...
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-08-11 | official-forward (B) | draft_guidance_availability_notice | "International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Caprines (Revision 1); Draft Guidance f" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry GFI #97 (VICH GL14(R1)) entitled "Effectiveness of Anthelmintics: Specific Recommendations for Caprines (Revision 1)." This draft guidance has been developed for veterinary use by the Int
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry GFI #97 (VICH GL14(R1)) entitled "Effectiveness of Anthelmintics: Specific Recommendations for Caprines (Revision 1)." This draft guidance has been developed for veterinary use by the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). This revision clarifies the definition of adequate infection in individual animals, updates considerations for field studies, and makes additional clarifying changes.
---
## SNAPSHOT Sa8ddcdf525
CUTOFF DATE (today): 2024-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Review of Drug Master Files in Advance of Certain Abbreviated New Drug Application Submissions Under Generic Drug User Fee Amendments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S4e3114fb81
CUTOFF DATE (today): 2022-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S3f6cb37e0e
CUTOFF DATE (today): 2026-06-26
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing use of historical price scenarios in stress testing for the Commodity Derivatives Segment
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Se02b382d8f
CUTOFF DATE (today): 2026-08-25
Regulator: SEBI (IN)
Matter: SEBI consultation: enhancements to the Straight-Through Processing framework for institutional trade messaging
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-05-19 | official-forward (B) | consultation_paper | "Consultation Paper on Easing of framework for Straight Through Processing (STP) of trades" | www.sebi.gov.in
   Claims: Seeks feedback on enhancements to the existing Straight-Through Processing (STP) framework to reduce latency and costs and enhance service delivery for market participants. / Describes STP as automating end-to-end processing of financial-instrument transactions, including Electronic Contract Notes (ECNs), across stock brokers, custodians and institutional investors. / Notes the existing STP architecture (involving Sender/Receiver STP Service Providers, 'SSPs') traces to SEBI circulars dated Feb 3 2004, Feb 25 2004, Apr 1 2004 and May 26 2004. / Identifies issues with the current STP architecture where different SSPs are used by each STP user.
   Excerpt: The objective of the consultation paper is to seek feedback on the enhancements in the existing Straight-Through Processing (STP) Framework to reduce the latency, costs and enhance service delivery for market participants. STP automates the end-to-end processing of transactions of the financial instruments. It involves use of a single system to process or control all elements of the work-flow of a financial transaction.
---
## SNAPSHOT S940574e6b9
CUTOFF DATE (today): 2021-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2019-09-23 | official-forward (B) | draft_guidance_availability_notice | "Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations." The Patient Engagement Advisory Committee (PEAC) recommended that FDA and industry develop some typ
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations." The Patient Engagement Advisory Committee (PEAC) recommended that FDA and industry develop some type of framework to clarify how patient advisors can engage in the clinical investigation process. This draft guidance focuses on the applications, perceived barriers, and common challenges of patient engagement in the design and conduct of medical device clinical investigations. This draft guidance is not final nor is it in effect at this time.
---
## SNAPSHOT Sc373754a32
CUTOFF DATE (today): 2023-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: The Use of Published Literature in Support of New Animal Drug Applications
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-04-20 | official-forward (B) | draft_guidance_availability_notice | "The Use of Published Literature in Support of New Animal Drug Applications; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry #106 entitled "The Use of Published Literature in Support of New Animal Drug Applications." This draft guidance, when finalized, will replace the existing final guidance #106, "The Use of
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry #106 entitled "The Use of Published Literature in Support of New Animal Drug Applications." This draft guidance, when finalized, will replace the existing final guidance #106, "The Use of Published Literature in Support of New Animal Drug Approval," which FDA published in August 2000 and which specifically addressed the use of a single article to support drug approval. This revision of the guidance document considers multiple uses of the scientific literature, including narrative reviews, systematic reviews, and meta-analyses to support approval of a new animal drug.
---
## SNAPSHOT Sba1cbd77ee
CUTOFF DATE (today): 2024-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning-Enabled Device Software Functions
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S1478dc44d8
CUTOFF DATE (today): 2022-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Digital Health Technologies for Remote Data Acquisition in Clinical Investigations
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2021-12-23 | official-forward (B) | draft_guidance_availability_notice | "Digital Health Technologies for Remote Data Acquisition in Clinical Investigations; Draft Guidance for Industry, Investigators, and Other Stakeholders; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry, investigators, and other stakeholders entitled "Digital Health Technologies for Remote Data Acquisition in Clinical Investigations." This guidance provides recommendations to sponsors, i
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry, investigators, and other stakeholders entitled "Digital Health Technologies for Remote Data Acquisition in Clinical Investigations." This guidance provides recommendations to sponsors, investigators, and other stakeholders on the use of digital health technologies (DHTs) to acquire data remotely from participants in clinical investigations evaluating medical products. DHTs may take the form of hardware and/or software and may be used to gather health-related information from study participants and transmit that information to study investigators and/or other authorized parties to evaluate the safety and effectiveness of medical products.
---
## SNAPSHOT S87fc543fe7
CUTOFF DATE (today): 2021-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted Under a Biologics License Application, New Drug Application, or Abbreviated New Drug ...
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-04-21 | official-forward (B) | draft_guidance_availability_notice | "Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted Under a Biologics License Application, New Drug Application, or Abbreviated New Drug Application; Draft Guidance for Industry an" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry and FDA entitled "Technical Considerations for Demonstrating Reliability of Emergency- Use Injectors Submitted under a BLA, NDA or ANDA." For injectable drug or biological products that a
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry and FDA entitled "Technical Considerations for Demonstrating Reliability of Emergency- Use Injectors Submitted under a BLA, NDA or ANDA." For injectable drug or biological products that are intended to treat emergent, life- threatening conditions, it is essential to ensure that the emergency- use injector will reliably deliver the drug or biological product as intended. This is particularly critical for drugs when failure of the injector may prevent adequate delivery of a life-saving drug to a patient. The draft guidance describes the technical considerations for demonstrating reliability of emergency-use injectors under a biologics license application (BLA), new drug application (NDA), or abbreviated new drug application (ANDA).
---
## SNAPSHOT S944402b02c
CUTOFF DATE (today): 2025-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2023-02-27 | official-forward (B) | draft_guidance_availability_notice | "Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment." This guidance is intended to provide recommendations to sponsors developing drugs intended to trea
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment." This guidance is intended to provide recommendations to sponsors developing drugs intended to treat neovascular age-related macular degeneration focusing on eligibility criteria, trial design considerations, and efficacy endpoints to enhance clinical trial data quality and to foster greater efficiency in development programs.
---
## SNAPSHOT Sd032f0aea0
CUTOFF DATE (today): 2020-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Instructions for Use-Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products-Content and Format
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sf30e963f9a
CUTOFF DATE (today): 2022-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-12-01 | official-forward (B) | draft_guidance_availability_notice | "Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications." This draft guidance focuses on specific 
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications." This draft guidance focuses on specific recommendations pertinent to gastric pH- dependent drug-drug interaction (DDI) assessment and describes the FDA's recommendations regarding when clinical DDI studies with acid- reducing agents (ARAs) are needed; design of the clinical studies; interpretation of study results; and communicating findings and options for managing pH-dependent DDIs in product labeling.
---
## SNAPSHOT Scfa0fe7968
CUTOFF DATE (today): 2026-08-25
Regulator: SEBI (IN)
Matter: SEBI consultation: draft circular on trading software/technology at stock exchanges and common IT provisions for market infrastructure institutions
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S42bfe4093a
CUTOFF DATE (today): 2026-06-26
Regulator: SEBI (IN)
Matter: SEBI consultation: harmonizing base price for pre-open call auction and price bands for stocks listed on multiple exchanges
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S17b657a094
CUTOFF DATE (today): 2020-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Peripheral Percutaneous Transluminal Angioplasty and Specialty Catheters-Premarket Notification (510(k)) Submissions
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-01-13 | official-forward (B) | draft_guidance_availability_notice | "Peripheral Percutaneous Transluminal Angioplasty and Specialty Catheters-Premarket Notification (510(k)) Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Peripheral Percutaneous Transluminal Angioplasty (PTA) and Specialty Catheters-- Premarket Notification (510(k)) Submissions; Draft Guidance for Industry and Food and Drug Administration S
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Peripheral Percutaneous Transluminal Angioplasty (PTA) and Specialty Catheters-- Premarket Notification (510(k)) Submissions; Draft Guidance for Industry and Food and Drug Administration Staff." The FDA is issuing this draft guidance document to provide recommendations for 510(k) submissions for peripheral percutaneous transluminal angioplasty (PTA) balloons and specialty catheters (e.g., infusion catheters, PTA balloon catheters for in-stent restenosis (ISR), scoring/cutting balloons). This draft guidance is not final nor is it in effect at this time.
---
## SNAPSHOT S0ccc30712e
CUTOFF DATE (today): 2023-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/Bioequivalence Studies
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2021-06-28 | official-forward (B) | draft_guidance_availability_notice | "Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/Bioequivalence Studies; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Sponsor Responsibilities--Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/ Bioequivalence Studies." The draft gu
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Sponsor Responsibilities--Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/ Bioequivalence Studies." The draft guidance provides recommendations for sponsors and sponsor-investigators to comply with the requirements of investigational new drug application (IND) safety reporting and safety reporting for bioavailability (BA) and bioequivalence (BE) studies. In doing so, the guidance provides recommendations related to the two IND safety reporting provisions that require assessment of aggregate data to facilitate appropriate IND safety reporting practices. An earlier draft guidance for industry entitled "Safety Assessment for IND Safety Reporting" (December 2015) (the 2015 draft guidance) has been incorporated into this draft guidance. However, this content was revised to address feedback from stakeholders and comments received on the 2015 draft guidance. Concurrent with the publication of this draft guidance, we are withdrawing the 2015 draft guidance. Additionally, this draft guidance incorporates c
---
## SNAPSHOT Sae1211a898
CUTOFF DATE (today): 2022-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Chronic Rhinosinusitis With Nasal Polyps: Developing Drugs for Treatment
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2021-12-10 | official-forward (B) | draft_guidance_availability_notice | "Chronic Rhinosinusitis With Nasal Polyps: Developing Drugs for Treatment; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatment." The purpose of this draft guidance is to assist sponsors in the clinical development of drugs for the 
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatment." The purpose of this draft guidance is to assist sponsors in the clinical development of drugs for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). Specifically, this draft guidance addresses FDA's current recommendations regarding trial design, safety, and efficacy considerations for CRSwNP clinical trials.